longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

NeuroPace

NPCE

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is -26.11, below the reasonable range, cheaper than 95.27% of the time in the past 3 years, and the industry ranks 149/175, the industry Median -0.94.

-26.11xP/E
$14.54Stock price
$-0.56Earnings per share
-26.11xP/E
Stock price$14.54Earnings per share$-0.56

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
-12.68x
Typical range
-22.26x–-6.93x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
012243648

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
P/E ratio
Name/Symbol
BAXUSBaxter
-11.15x141.71%$11.85B
GKOSUSGlaukos
-50.67x75.37%$9.53B
TFXUSTeleflex
-5.13x118.39%$5.29B
PLSEUSPulse Biosciences
-47.49x27.55%$3.80B
IRTCUSIRhythm
-260.88x71.96%$3.64B
AXGNUSAxogen
-80.33x31.25%$2.69B
BFLYUSButterfly Network
-28.96x34.41%$2.17B
ASSTUSStrive
-2.15x63.26%$2.10B
NVCRUSNovocure
-12.96x2.52%$1.92B
ATECUSAlphatec
-14.28x41.67%$1.57B
KMTSUSKestra Medical Tech
-9.69x0.94%$1.45B
DRTSUSAlpha Tau Medical
-15.46x--$1.43B
TNDMUSTandem Diabetes
-19.36x77.82%$1.23B
IARTUSIntegra LifeSciences
-167.54x109.50%$1.21B
BBNXUSBeta Bionics
-15.90x15.43%$1.16B
AORTUSArtivion
-361.05x266.67%$1.15B
PRCTUSPROCEPT BioRobotics
-9.66x3.47%$1.06B
ENOVUSEnovis
-0.94x100.97%$1.04B
CBLLUSCeribell
-14.10x35.15%$930.67M
SIBNUSSI-BONE
-56.51x8.85%$826.90M

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.